van Tilburg, Cornelis M. http://orcid.org/0000-0001-5274-910X
Milde, Till
Witt, Ruth
Ecker, Jonas
Hielscher, Thomas
Seitz, Angelika
Schenk, Jens-Peter
Buhl, Juliane L.
Riehl, Dennis
Frühwald, Michael C.
Pekrun, Arnulf
Rossig, Claudia
Wieland, Regina
Flotho, Christian
Kordes, Uwe
Gruhn, Bernd
Simon, Thorsten
Linderkamp, Christin
Sahm, Felix
Taylor, Lenka
Freitag, Angelika
Burhenne, Jürgen
Foerster, Kathrin I.
Meid, Andreas D.
Pfister, Stefan M.
Karapanagiotou-Schenkel, Irini
Witt, Olaf
Funding for this research was provided by:
Deutsche Kinderkrebsstiftung (DKS 2009.16)
Article History
Received: 3 August 2019
Accepted: 3 November 2019
First Online: 10 December 2019
Ethics approval and consent to participate
: The final protocol, amendments, and informed consent and any other appropriate documents were reviewed and approved by the Independent Ethics Committee(s) (IEC) at each of the investigational centers (reference number Heidelberg University Hospital: AFmu-286/2008) participating in the study and the German competent authority (BfArM). The study was conducted in accordance with the principles of the Declaration of Helsinki and the Good Clinical Practice guidelines of the International Conference on Harmonization and in keeping with local legal and regulatory requirements. Written informed consent was obtained prior to the patient entering the trial.
: Not applicable.
: C.M.v.T. participated in Novartis and Bayer advisory boards.C.R. participated in Amgen, Novartis, Pfizer, Roche, Genentech, Celgene, and SHIRE advisory boards.J.B. received speech honoraria and travel support for scientific meetings from MSD Sharp & Dohme.O.W. participated in AstraZeneca and Novartis advisory boards.T.S. participated in Merck and EUSA Pharma advisory boards.The other authors declare that they have no competing interests.